Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.63 -3.7%	$2.45	$1.78 ▼ $10.14	$54.94M	0.7	262,158 shs	112,704 shs
AERI Aerie Pharmaceuticals	$15.25	$15.23	$4.81 ▼ $15.37	$753.61M	-0.06	974,748 shs	600 shs
DBVT DBV Technologies	$10.16 -0.6%	$9.63	$2.20 ▼ $12.78	$278.28M	-0.59	191,266 shs	21,292 shs
MESO Mesoblast	$10.96 -1.9%	$11.20	$5.78 ▼ $22.00	$1.40B	2.39	277,503 shs	72,031 shs
VCEL Vericel	$37.10 -6.8%	$41.88	$36.97 ▼ $63.00	$1.87B	1.32	423,575 shs	645,691 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+7.48%	+22.42%	+10.98%	-15.48%	-65.49%
AERI Aerie Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
DBVT DBV Technologies	-2.07%	-3.94%	+16.22%	+43.89%	+164.40%
MESO Mesoblast	+0.54%	+6.08%	-5.18%	+3.71%	+38.76%
VCEL Vericel	-0.28%	+1.04%	-6.68%	-5.21%	-17.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.5405 of 5 stars	3.4	4.0	0.0	4.8	2.7	2.5	0.6
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	3.9844 of 5 stars	4.4	5.0	0.0	0.0	2.3	2.5	0.6
MESO Mesoblast	2.332 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.6
VCEL Vericel	3.7273 of 5 stars	3.5	5.0	0.0	0.0	3.7	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	804.94% Upside
AERI Aerie Pharmaceuticals	0.00	N/A	N/A	N/A
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	45.18% Upside
MESO Mesoblast	3.00	Buy	$18.00	64.23% Upside
VCEL Vericel	3.00	Buy	$61.14	64.81% Upside

Current Analyst Ratings Breakdown

Latest ADVM, VCEL, DBVT, AERI, and MESO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/16/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/22/2025	VCEL Vericel	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$67.00 ➝ $67.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	54.94	N/A	N/A	$3.40 per share	0.77
AERI Aerie Pharmaceuticals	$194.13M	3.88	N/A	N/A	($3.32) per share	-4.59
DBVT DBV Technologies	$4.15M	67.06	N/A	N/A	$1.42 per share	7.15
MESO Mesoblast	$5.90M	237.37	N/A	N/A	$4.21 per share	2.60
VCEL Vericel	$238.54M	7.83	$0.29 per share	127.78	$5.92 per share	6.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
AERI Aerie Pharmaceuticals	-$74.81M	-$0.77	N/A	N/A	N/A	-17.09%	N/A	-2.00%	N/A
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
VCEL Vericel	$10.36M	$0.03	1,237.08	84.32	N/A	1.25%	1.09%	0.73%	7/30/2025 (Estimated)

Latest ADVM, VCEL, DBVT, AERI, and MESO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	VCEL Vericel	-$0.04	N/A	N/A	N/A	$64.61 million	N/A
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.28	N/A	N/A	N/A	$0.64 million	N/A
5/8/2025	Q1 2025	VCEL Vericel	-$0.09	-$0.23	-$0.14	-$0.23	$53.86 million	$52.60 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
AERI Aerie Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
AERI Aerie Pharmaceuticals	N/A	2.27	1.92
DBVT DBV Technologies	N/A	0.72	0.72
MESO Mesoblast	0.22	0.96	0.63
VCEL Vericel	N/A	5.01	4.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
AERI Aerie Pharmaceuticals	95.94%
DBVT DBV Technologies	71.74%
MESO Mesoblast	1.43%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
AERI Aerie Pharmaceuticals	4.44%
DBVT DBV Technologies	1.44%
MESO Mesoblast	18.80%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
AERI Aerie Pharmaceuticals	376	49.42 million	47.22 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
VCEL Vericel	300	50.34 million	46.72 million	Optionable

ADVM, VCEL, DBVT, AERI, and MESO Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Shares Down 4.8% - What's Next?

July 15 at 2:10 PM | marketbeat.com

New York State Common Retirement Fund Increases Position in Vericel Corporation (NASDAQ:VCEL)

July 15 at 5:16 AM | marketbeat.com

TimesSquare Capital Management LLC Increases Stake in Vericel Corporation (NASDAQ:VCEL)

July 14 at 8:50 AM | marketbeat.com

Principal Financial Group Inc. Buys 7,222 Shares of Vericel Corporation (NASDAQ:VCEL)

July 14 at 3:49 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives $61.14 Average Price Target from Analysts

July 5, 2025 | americanbankingnews.com

Allspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)

July 4, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from Brokerages

July 2, 2025 | marketbeat.com

Lisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)

June 29, 2025 | marketbeat.com

If EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An Opportunity

June 20, 2025 | finance.yahoo.com

Conestoga Capital Advisors LLC Sells 7,830 Shares of Vericel Co. (NASDAQ:VCEL)

June 17, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?

June 16, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Receives "Overweight" Rating from Stephens

June 16, 2025 | marketbeat.com

Vericel Corporation: Moving From Sell To Neutral

June 12, 2025 | seekingalpha.com

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 11, 2025 | morningstar.comM

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025

June 10, 2025 | globenewswire.com

5VCEL : What Analysts Are Saying About Vericel Stock

May 23, 2025 | benzinga.com

Vericel at BofA Securities Conference: Growth and Innovation in Healthcare

May 16, 2025 | investing.com

Which Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?

May 10, 2025 | aaii.comA

Vericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

May 9, 2025 | finanznachrichten.de

Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...

May 9, 2025 | finance.yahoo.com

Vericel Corporation 2025 Q1 - Results - Earnings Call Presentation

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADVM, VCEL, DBVT, AERI, and MESO Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.63 -0.10 (-3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$2.62 -0.01 (-0.23%)

As of 07:28 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Aerie Pharmaceuticals NASDAQ:AERI

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

DBV Technologies NASDAQ:DBVT

$9.82 -0.40 (-3.86%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Mesoblast NASDAQ:MESO

$10.96 -0.21 (-1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$10.96 0.00 (0.00%)

As of 07:39 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Vericel NASDAQ:VCEL

$37.10 -2.72 (-6.83%)

Closing price 04:00 PM Eastern

Extended Trading

$37.29 +0.19 (+0.51%)

As of 07:32 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time